As of July this year, based on Johnson & Johnson's most recent financial report, the company's trailing twelve months EPS is $9.41. Johnson & Johnson's earnings per share in 2024 was reported at $5.84, marking a decline from $13.88 in 2023. Johnson & Johnson's EPS for the quarterly period ending on Jun 29, 2025 came in at $2.3.
The yearly earnings per share during 2024 was $5.84, a decline of 57.9% compared to $13.88 recorded in 2023. The quarterly earnings per share for the period ending Jun 29, 2025, was $2.3, showing a 17.9% increase compared to the same quarter last year. The trailing twelve months EPS for JNJ is $9.41 as of June 2025. Johnson & Johnson's full-year EPS for 2023 was $13.88, a 103.2% rise compared to the previous year.
In the past 12 months, Johnson & Johnson has recorded an earnings per share growth rate of 17.9% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of -9.7% per year. In the last five years, the company had an average annual EPS growth of 0.4%. When assessed over a ten-year period, JNJ's average EPS annual growth was 0.1%.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
MRK Merck & Co Inc | 12.29 | 4,728.6% | 9.4% | 12% |
ABT Abbott Laboratories | 16.32 | 133.8% | 24.5% | 29.9% |
NVS Novartis AG | 16.94 | -17.2% | -17.9% | 2.9% |
PFE Pfizer Inc | 17.82 | 273.7% | -28.7% | -13.2% |
JNJ Johnson & Johnson | 17.82 | -57.9% | -9.7% | 0.4% |
GILD Gilead Sciences Inc | 24.4 | -91.6% | -57.5% | -38.3% |
MDT Medtronic plc | 25.57 | 31% | -1.1% | 0.3% |
SYK Stryker Corp | 53.46 | -5.8% | 14.1% | 7.1% |
LLY ELI LILLY & Co | 65.33 | 102.1% | 24.1% | 5.7% |
All data is based on quarterly TTM periods, unless otherwise specified.